Division of Immunology, Paul-Ehrlich-Institute, Federal Institute for Vaccines and Biomedicines, Langen, 63225, Hesse, Germany.
Department of Chemistry, RPTU Kaiserslautern-Landau, Kaiserslautern, 67663, Rhineland-Palatinate, Germany.
Trends Pharmacol Sci. 2024 Nov;45(11):1061-1080. doi: 10.1016/j.tips.2024.09.009. Epub 2024 Oct 25.
Nitro-fatty acids (NO-FAs) are endogenous pleiotropic lipid mediators regarded as promising drug candidates for treating inflammatory and fibrotic diseases. Over the past two decades, the anti-inflammatory and cytoprotective actions of NO-FAs and several molecular targets have been identified. More recently, preclinical studies have demonstrated their potential as prospective cancer therapeutics with favorable safety and tumor-selective profiles. In this review, we describe the mechanisms of action, with a focus on NO-FA antineoplastic and chemosensitizing effects. We also address the potential therapeutic applications of endogenous and structurally modified NO-FAs species in cancer treatment.
硝酰基脂肪酸（NO-FAs）是内源性多效脂质介质，被认为是治疗炎症和纤维化疾病的有前途的药物候选物。在过去的二十年中，已经确定了 NO-FAs 的抗炎和细胞保护作用及其几个分子靶标。最近，临床前研究表明，它们具有作为有前景的癌症治疗剂的潜力，具有良好的安全性和肿瘤选择性特征。在这篇综述中，我们描述了作用机制，重点介绍了 NO-FA 的抗肿瘤和化疗增敏作用。我们还讨论了内源性和结构修饰的 NO-FAs 物种在癌症治疗中的潜在治疗应用。
